전이성 유방암 환자에서 Cisplatin과 Etoposide 항암화학요법을 이용한 치료
Treatment with Cisplatin and Etoposide Chemotherapy in Patient with Metastatic Breast Cancer
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Both the incidence of breast cancer as well as, the number of patients with metastatic breast cancer has increased. Taxane and anthracycline chemotherapy is known to be effective in metastatic breast cancer; however, the subsequent treatment option when such treatment fails remains unestablished. The aim of the present study was to analyze the effect and response of cisplatin and etoposide treatment along with the predictive factor for patients who failed taxane and anthracycline chemotherapy for metastatic breast cancer. Methods: Forty-three patients with breast cancer whose regimen was changed to cisplatin and etoposide chemotherapy from taxane and anthracycline chemotherapy owing to treatment failure were included in this study. The chemotherapy regimen consisted of intravenous injection of 100 mg/m2 etoposide and 70 mg/m2 cisplatin on day 1 and then intravenous injection of 100 mg/m2 etoposide on days 2 and 3. This cisplatin and etoposide chemotherapy was repeated at 3 week intervals, and patients were assessed after the 2nd or 3rd cycle of therapy to evaluate the tumor response. Results: The average cycle and progression-free survival of cisplatin and etoposide chemotherapy were 4±3.1 (range, 1–16) and 12±14.2 weeks (range, 0–60 weeks), respectively. The average overall survival was 44±33.9 months (range, 11–149 months). The treatment response group consisted of 23 patients (53.5%) who continuously received cisplatin and etoposide chemotherapy for over four cycles, while the non-response group consisted of 20 patients (46.5%) who underwent three or fewer cycles of chemotherapy. Patients with excellent response to cisplatin and etoposide chemotherapy also showed good response to taxane and anthracycline chemotherapy (p=0.011). Conclusion: In patients who show good response to taxane and anthracycline chemotherapy, cisplatin and etoposide chemotherapy is also expected to have a positive result.
Abstract
Purpose: Both the incidence of breast cancer as well as, the number of patients with metastatic breast cancer has increased. Taxane and anthracycline chemotherapy is known to be effective in metastatic breast cancer; however, the subsequent treatment option when such treatment fails remains unestablished. The aim of the present study was to analyze the effect and response of cisplatin and etoposide treatment along with the predictive factor for patients who failed taxane and anthracycline chemotherapy for metastatic breast cancer. Methods: Forty-three patients with breast cancer whose regimen was changed to cisplatin and etoposide chemotherapy from taxane and anthracycline chemotherapy owing to treatment failure were included in this study. The chemotherapy regimen consisted of intravenous injection of 100 mg/m2 etoposide and 70 mg/m2 cisplatin on day 1 and then intravenous injection of 100 mg/m2 etoposide on days 2 and 3. This cisplatin and etoposide chemotherapy was repeated at 3 week intervals, and patients were assessed after the 2nd or 3rd cycle of therapy to evaluate the tumor response. Results: The average cycle and progression-free survival of cisplatin and etoposide chemotherapy were 4±3.1 (range, 1–16) and 12±14.2 weeks (range, 0–60 weeks), respectively. The average overall survival was 44±33.9 months (range, 11–149 months). The treatment response group consisted of 23 patients (53.5%) who continuously received cisplatin and etoposide chemotherapy for over four cycles, while the non-response group consisted of 20 patients (46.5%) who underwent three or fewer cycles of chemotherapy. Patients with excellent response to cisplatin and etoposide chemotherapy also showed good response to taxane and anthracycline chemotherapy (p=0.011). Conclusion: In patients who show good response to taxane and anthracycline chemotherapy, cisplatin and etoposide chemotherapy is also expected to have a positive result.
참고문헌 (22)
- 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2014", Cancer Research and Treatment, 49(2), pp.292~305 (2017), 대한암학회
- 김지선, "The Basic Facts of Korean Breast Cancer in 2012: Results from a Nationwide Survey and Breast Cancer Registry Database", Journal of Breast Cancer, 18(2), pp.103~111 (2015), 한국유방암학회
- Bernard-Marty C, "Facts and controversies in systemic treatment of metastatic breast cancer", Oncologist, 9, pp.617~632 (2004)
- Kamangar F, "Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world", J Clin Oncol, 24, pp.2137~2150 (2006)
- Esteva FJ, "Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond", Oncologist, 6, pp.133~146 (2001)
- Pronzato P, "First line chemotherapy of metastatic breast cancer", Ann Oncol, 17(5), pp.v165~v168 (2006)
- Decatris MP, "Platinum-based chemotherapy in metastatic breast cancer: the Leicester (U.K.) experience", Clin Oncol (R Coll Radiol), 17, pp.249~257 (2005)
- Crown J, "Chemotherapy for metastatic breast cancer: report of a European expert panel", Lancet Oncol, 3, pp.719~727 (2002)
- Cocconi G, "Cisplatin and etoposide as first-line chemotherapy for metastatic breast carcinoma: a prospective randomized trial of the Italian Oncology Group for Clinical Research", J Clin Oncol, 9, pp.664~669 (1991)
- Go RS, "Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin", J Clin Oncol, 17, pp.409~422 (1999)
- Roché H, "Treatment of metastatic breast cancer: second line and beyond", Ann Oncol, 22, pp.1000~1010 (2011)
- Gordaliza M, "Podophyllotoxin: distribution, sources, applications and new cytotoxic derivatives", Toxicon, 44, pp.441~459 (2004)
- Decatris MP, "Platinum-based chemotherapy in metastatic breast cancer: current status", Cancer Treat Rev, 30, pp.53~81 (2004)
- Cocconi G, "Platinum and etoposide in chemotherapy refractory metastatic breast cancer: a phase II trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.)", Eur J Cancer Clin Oncol, 22, pp.761~764 (1986)
- Durand RE, "Interaction of etoposide and cisplatin in an in vitro tumor model", Cancer Treat Rep, 71, pp.673~679 (1987)
- Lluch A, "Phase II trial of cisplatin and etoposide as first-line therapy in metastatic breast carcinoma", Oncology, 51, pp.352~355 (1994)
- Eisenhauer EA, "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)", Eur J Cancer, 45, pp.228~247 (2009)
- Howlader N, "Overview of breast cancer collaborative stage data items: their definitions, quality, usage, and clinical implications: a review of SEER data for 2004-2010", Cancer, 120(23), pp.3771~3780 (2014)
- Fried G, "Clinical activity of cisplatin and prolonged oral administration of etoposide in previously treated, anthracycline-resistant, metastatic breast cancer patients: a phase II study", Med Pediatr Oncol, 34, pp.10~13 (2000)
- Franciosi V, "Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study", Cancer, 85, pp.1599~1605 (1999)
- Martín M, "Platinum compounds in the treatment of advanced breast cancer", Clin Breast Cancer, 2, pp.190~208 (2001)
- Tian M, "Platinum-based therapy for triple-negative breast cancer treatment: a meta-analysis", Mol Clin Oncol, 3, pp.720~724 (2015)